Analysts are showing heightened interest in Cencora, Inc. (COR), raising both ratings and price targets, indicative of a positive growth story. The company's focus on rare disease services, particularly through its collaboration with Curant, is magnetizing investors. Major banks such as Morgan Stanley and Jefferies have also upgraded Cencora's stock, reflecting its strong growth outlook. Moreover, several large institutional investors including Bank of New York Mellon Corp, AustralianSuper Pty Ltd, and Retirement Systems of Alabama have increased their stake in Cencora, signaling substantial confidence in the firm. They slightly retreat 6.3% after the last earnings report because of a $713M one-off loss, although it continues to generate positive investor interest due to its high growth and financial model adjustments. Furthermore, Cencora's logistic expansion and earnings upgrades have spurred additional investor interest. Despite a recent stock consolidation, there is a 25% upside speculation. Cencora recently announced acquisition highlights, including majority control of cancer care network OneOncology for $5 billion, expanding its global reach with Alliance Healthcare Acquisition, and planned $1 billion investment in US drug distribution. These indicators and activities provide ongoing momentum for the biotech company.
Cencora COR News Analytics from Tue, 01 Jul 2025 07:00:00 GMT to Sat, 31 Jan 2026 14:46:57 GMT -
Rating 7
- Innovation 4
- Information 8
- Rumor 3
